Chat, Vylyny
Ferguson, Robert
Simpson, Danny
Kazlow, Esther
Lax, Rebecca
Moran, Una
Pavlick, Anna
Frederick, Dennie
Boland, Genevieve
Sullivan, Ryan
Ribas, Antoni
Flaherty, Keith
Osman, Iman
Weber, Jeffrey
Kirchhoff, Tomas
Funding for this research was provided by:
National Institutes of Health (1R21CA184432-01)
Article History
Received: 31 October 2018
Accepted: 27 February 2019
First Online: 12 March 2019
Compliance with ethical standards
:
: No conflict of interest, except for: Antoni Ribas has received honoraria from consulting with Bristol Myers Squibb, Amgen, Chugai, Genentech, Merck, Novartis and Roche, is in the scientific advisory board of Advaxis, Arcus, Bioncotech, Compugen, CytomX, Five Prime, FLX-Bio, ImaginAb, Isoplexis, Merus and Rgenix, during the conduct of this work was in the scientific advisory board and held stock in Kite-Pharma, and is co-founder of PACT Pharma and Tango Therapeutics. Ryan Sullivan serves as a Consultant/Advisory Board member at Merck, Amgen, Compugen, Array Biopharma, Novartis, Roche-Genentech and Replimmune, Syndax, and received research support from Merck, Amgen. Keith Flaherty serves on the Board of Directors of Loxo Oncology, Clovis Oncology, Strata Oncology and Vivid Biosciences; on the Corporate Advisory Boards of X4 Pharmaceuticals and PIC Therapeutics; on the scientific advisory boards of Sanofi, Amgen, Asana, Adaptimmune, Fount, Aeglea, Array BioPharma, Shattuck Labs, Arch Oncology, Tolero, Apricity, Oncoceutics, Fog Pharma, Neon Therapeutics, and Tvardi; and as a consultant to Novartis, Genentech, BMS, Merck, Takeda, Verastem, Checkmate, Boston Biomedical, Pierre Fabre, Cell Medica, and Debiopharm. Jeffrey Weber owns stock or other ownership at Altor BioScience, Biond, CytomX Therapeutics, received honoraria from Bristol-Myers Squibb, Merck, Genentech, AbbVie, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Eisai, Altor BioScience, Amgen, Roche, Ichor Medical Systems, Celldex, CytomX Therapeutics, Nektar, Novartis, Sellas, WindMIL, Takeda, has consulting/advisory role at Celldex, Ichor Medical Systems, Biond, Altor BioScience, Bristol-Myers Squibb, Merck, Genentech, Roche, Amgen, AstraZeneca, GlaxoSmithKline, Daiichi Sankyo, AbbVie, Eisai, CytomX Therapeutics, Nektar, Novartis, Sellas, WindMIL, Takeda, and obtained research funding (to the Institution) from Bristol-Myers Squibb, Merck, GlaxoSmithKline, Genentech, Astellas Pharma, Incyte, Roche, Novartis and received funding for travel/accommodations/expenses from Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Roche, Celldex, Amgen, Merck, AstraZeneca, Genentech, Novartis, WindMIL, Takeda.
: Written informed consents for the use of the blood specimens and clinical information were obtained at the time of enrollment from all participants and the study was approved by the Institutional Review Board (IRB) at all institutions (NYULH: IRB#10362; MGH/Dana Farber/Harvard Cancer Center: IRB#11–181; UCLA: IRB#11-001918 and 11-003066).